Targeting catechol-O-methyl transferase (COMT) inhibitors for schizophrenia: An approach to target validation and rational drug design

Letters in Drug Design and Discovery

Volumn 8, Issue 3, 2011, Pages 246-252

  Purushotham, Deepak ^a   Ganguly, Chaiti ^a   Chakraborty, Chiranjib ^a  

^a Department of Biotechnology   (India)

Author keywords

Catechol O methyl transferase (COMT); Docking; Rational drug design; Schizophrenia; Target validation; Zebrafish

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 7,8 DIHYDROXYFLAVONE; ACACETIN; ACICLOVIR; ALPHA TOCOPHEROL; APIGENIN; ASCORBIC ACID; BIOCHANIN A; BUTEIN; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DAIDZEIN; DIFLUNISAL; DIOXYBENZONE; FORMONONETIN; GENISTEIN; HYDROGEN; IODO METHOXY AG538; KAEMPFEROL; LAVENDUSTIN C; LYSINE; NICLOSAMIDE; OXYBENZONE; PARACETAMOL; SODIUM 5 (DIFLUOROMETHOXY) 2 [[(3,4 DIMETHOXY 2 PYRIDINYL)METHYL]SULFINYL] 1H BENZIMIDAZOLE; TECTORIGENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; EMBRYO; EMBRYO DEVELOPMENT; HUMAN; HYDROGEN BOND; LARVA; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; ZEBRA FISH;

EID: 79952292905     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011794578277     Document Type: Article

References (39)

1. Jablensky, A.; Sartorius, N.; Ernberg, G.; Anker, M.; Korten, A.; Cooper, J.E.; Day, R.; Bertelsen, A. Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol. Med. Monogr. Suppl., 1992, 20, 1-97.
2. Rice, D.P. The economic impact of schizophrenia. J. Clin. Psychiatry, 1999, 60, 4-6. (Pubitemid 29072616)
3. Andreasen, N.C. Schizophrenia: The fundamental questions. Brain Res. Rev., 2000, 31,106-112.
4. Snyder, S.H.; Banerjee, S.P.; Yamamura, H.I.; Greenberg, D. Drugs, neurotransmitters, and schizophrenia. Science, 1974, 184, 1243-1253.
5. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 1988, 1, 179-186. (Pubitemid 19126130)
6. Duncan, G.E.; Sheitman, B.B.; Lieberman, J.A. An integrated view of pathophysiological models of schizophrenia. Brain Res. Rev., 1999, 29, 250-264. (Pubitemid 29191342)
7. Seeman, P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1987,1,133-152. (Pubitemid 17119661)
8. Miyamoto, S.; Mailman, R.B.; Lieberman, J.A.; Duncan, G.E. Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors. Brain Res., 2001, 894,167-180. (Pubitemid 32218729)
9. Laruelle, M.; Abi-Dargham, A.; Gil, R.; Kegeles, L.; Innis, R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol. Psychiatry, 1999, 46,56-72. (Pubitemid 29296818)
10. Tandon, R.; Nasrallah, H.A.; Keshavan, M.S. Schizophrenia,"just the facts"4. clinical featuresand conceptualization. Schizophr. Res., 2009,110, 1-23.
11. Weinberger, D.R.; Egan, M.F.; Bertolino, A.; Callicott, J.H., Mattay, V.S.; Lipska, B.K.; Berman, K.F.; Goldberg, T.E. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry., 2001, 50, 825-844. (Pubitemid 34020697)
12. Liljequist, R.; Haapalinna, A.; Ahlander, M.; Li, Y.H.; Mannisto, P.T. Catechol-O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav. Brain Res., 1997, 82,195-202.
13. Gasparini, M.; Fabrizio, E.; Bonifati, V.; Meco, G.J. Cognitive improvement during tolcapone treatment in Parkinson's disease. Neural. Transm., 1997, 104,887-894.
14. Gogos, J.A.; Morgan, M.; Luine, V.; Santha, M.; Ogawa, S.; Pfaff, D.; Karayiorgou, M. Catechol-Omethyltransferase- deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. USA., 1998 , 95,9991-9996.
15. Tandon, R.; Nasrallah, H.A.; Keshavan, M.S. Schizophrenia, "just the facts" 5. treatment and prevention. past, present, and future. Schizophr. Res., 2010, 122, 1-23.
16. Walters, W.P.; Stahl, M.T.; Murcko, M.A. Virtual screening - an overview. Drug Discov. Today., 1998, 3,160-178. (Pubitemid 128715971)
17. Kuntz, I.D.; Blaney, J.M.; Oatley, S.J.; Langridge, R.; Ferrin, T.E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol., 1982, 161, 269-288.
18. Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem. Int. Ed., 2002, 41,2644-2676.
19. Lundström, K.; Tenhunen, J.; Tilgmann, C.; Karhunen, T.; Panula, P.; Ulmanen, I. Cloning, expression and structure of catechol-O-methyltransferase. Biochim. Biophys. Acta Prot. Struct. Mol. Enzymol., 1995,1251, 1-10.
20. Bertocci, B.; Miggiano, V.; Da Prada, M.; Dembic, Z.; Lahm, H.W.; Malherbe, P. Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc. Natl. Acad. Sci. USA, 1991, 88, 1416-1420. (Pubitemid 21916235)
21. Lundström, K.; Salminen, M.; Jalanko, A.; Savolainen, R.; Ulmanen, I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol., 1991, 10, 181-189.
22. Higgins, D.; Thompson, J.; Gibson, T.; Thompson, J.D.; Higgins, D.G.; Gibson, T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res., 1994, 22,4673-4680.
23. Guex, N.; Peitsch, M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis, 1997, 18, 2714-2723
24. Guex, N.; Diemand, A.; Peitsch, M.C. Protein modelling for all. Trends Biochem. Sci., 1999, 24,364-367
25. Schwede, T.; Diemand, A.; Guex, N.; Peitsch, M.C. Protein structure computing in the genomic era. Res. Microbiol., 2000, 151, 107-112 (Pubitemid 30366696)
26. Sayle, R.A.; Milner-White, E.J. RASMOL: biomolecular graphics for all. Trends in Biochemical Sciences ,1995, 20,374-883
27. Laurie, A.T.; Jackson, R.M. Q-SiteFinder: an energy-based method for the rediction of protein-ligand binding sites. Bioinformatics, 2005, 21,1908-1916.
28. von Grotthuss, M.; Koczyk, G.; Pas, J.; Wyrwicz, L.S.; Rychlewski, L. Ligand. Info small-molecule meta-database. Comb. Chem. High. Throughput., 2004, 7,757
29. Melo, F.; Feytmans, E. Novel knowledge-based mean force potential at atomic level. J. Mol. Biol., 1997, 267, 207-222. (Pubitemid 27149749)
30. Sippl, M. J. Calculation of conformational ensembles from potentials of mean force: an approach to the knowledge based prediction of local structures in globular proteins. J. Mol. Biol., 1990, 213,859-883. (Pubitemid 20213222)
31. von Grotthuss, M.; Pas, J.; Rychlewski, L. Ligand-Info, searching for similar small compounds using index profiles. Bioinformatics, 2003, 19,1041-1042.
32. Joy, S.; Nair, P.S.; Hariharan, R.; Pillai, M.R. Detailed comparison of the protein-ligand docking efficiencies of GOLD, a commercial package and ArgusLab, a licensable freeware. In Silico Biology, 2006, 6, 601-605 (Pubitemid 47028648)
33. Peterson, R.T.; Link, B.A.; Dowling, J.E.; Schreiber, S.L. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc. Natl. Acad. Sci. USA., 2000, 97, 12965-12969.
34. Stern, H.M.; Murphey, R.D.; Shepard, J.L.; Amatruda, J.F. Straub, C.T.; Pfaff, K.L.; Weber, G.; Tallarico, J.A.; King, R.W.; Zon, L.I. Small molecules that delayS phase suppress a zebrafish bmyb mutant. Nat. Chem. Biol., 2005, 1,366-370.
35. Laplante, M.; Kikuta, H.; König, M.; Becker, T.S. Enhancer detection in the zebrafish using pseudotyped murine retroviruses. Methods, 2006, 39,189-198 (Pubitemid 44189884)
36. Rivett, A.J.; Roth, J.A. Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase. Biochemistry, 1982, 21,1740-1742. (Pubitemid 12084091)
37. Lotta, T.; Vidgren, J.; Tilgmann, C.; Ulmanen, I.; Melén, K.; Julkunen, I.; Taskinen, J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme Biochemistry, 1995, 34,4202-4210.
38. Ovaska, M.; Yliniemelä, A. A semiempirical study on inhibition of catechol O-methyltransferase by substituted catechols. J. Comput. Aided. Mol. Des. 1998, 12, 301-307. (Pubitemid 128510958)
39. Blum, J.; Nkunku, S.; Burri, C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop. Med. Int. Health., 2001, 6, 390-400. (Pubitemid 32510076)